Building on research from Imperial College London, we develop radiopharmaceuticals for cancer diagnosis and treatment, designed for reliable production and wider patient access.
Emerging from Imperial College London's Aboagye lab, NuclearMediX advances radiopharmaceuticals based on click chemistry for cancer diagnosis and treatment.
We bridge validated science with scalable manufacturing and real-world clinical access.
Explore our FAQs
Professor of Cancer Pharmacology & Molecular Imaging at Imperial College London and inventor of the FETO SSTR-PET tracer, its latest synthesis and cassette-enabled radiohalogen labelling methods. 28 years of PET research since joining Imperial, with 16+ patents, 378+ published articles and multiple radiopharmaceuticals translated into clinical trials.
Entrepreneurial lead and radiopharmaceutical scientist with experience from lead selection to preclinical development and translation, specialising in radioconjugates of small molecules, peptides and antibodies.
Director of early phase cancer imaging trials; Consultant Medical Oncologist at Imperial College.
30+ years in radiopharmaceutical R&D; former senior roles at GE HealthCare and former CEO of Edinburgh Molecular Imaging.
Radiochemistry development and technology transfer; clinical development experience in radiopharmaceuticals.
25+ years radiopharmaceutical R&D and commercialisation; CEO of Edinburgh Molecular Imaging.
PhD in Molecular Biology and Oncology, with over 10 years in academic research. Supports translational funds, industry collaboration, IP protection, marketing, licensing, and spin-outs.
We focus on clinically proven targets to de-risk development.
Chemistry is engineered for automation from day one.
Cassette-based synthesis ensures reproducible quality.
Collaboration drives faster access for patients.